CDT Equity (CDT) Other Non-Current Assets (2022 - 2026)
CDT Equity's (CDT) quarterly Other Non-Current Assets came in at $781000.0 in Q1 2026, down 28.81% YoY from $1.1 million in Q1 2025, and down 9.19% on a QoQ basis from $860000.0 in Q4 2025.
CDT Equity (CDT) Other Non-Current Assets (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Other Non-Current Assets data on file, last reported at $781000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 28.81% year-over-year to $781000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $781000.0 (down 28.81% YoY) and the FY2025 annual result came in at $860000.0, down 26.81% from the prior year.
- Other Non-Current Assets eased to $781000.0 in Q1 2026, from $860000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.6 million in Q3 2023 to a low of $45302.0 in Q2 2022.
- A 5-year average of $828809.6 and a median of $939000.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 93.12% — and 2025, when it surged 842.59%.
- Tracing CDT's Other Non-Current Assets over 5 years: stood at $45302.0 in 2022, then surged by 3191.25% to $1.5 million in 2023, then declined by 21.19% to $1.2 million in 2024, then dropped by 26.81% to $860000.0 in 2025, then declined by 9.19% to $781000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $781000.0 (Q1 2026), $860000.0 (Q4 2025), and $939000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 702,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 702,000.00 |
| Mar 31, 2026 | 781,000.00 |
| Dec 31, 2025 | 860,000.00 |
| Sep 30, 2025 | 939,000.00 |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2022 | 45,302.00 |
| Mar 31, 2022 | 167,223.00 |